Assessment of OMT-28, a synthetic analog of omega-3 epoxyeicosanoids, in patients with persistent atrial fibrillation: Rationale and design of the PROMISE-AF phase II study

Autor: Sarah Berlin, Andreas Goette, Luciana Summo, Janine Lossie, Alexander Gebauer, Naab Al-Saady, Leonardo Calo, Gerald Naccarelli, Wolf-Hagen Schunck, Robert Fischer, A.John Camm, Dobromir Dobrev

Publikováno v: International Journal of Cardiology: Heart & Vasculature, Vol 29, Iss , Pp 100573- (2020)

We designed a placebo controlled, double-blind, randomized, dose-finding phase II study on OMT-28 in the maintenance of sinus rhythm after electrical cardioversion (DCC) in patients with persistent atrial fibrillation (PROMISE-AF). OMT-28 is a first-

Externí odkaz: https://doaj.org/article/fea19d454d8e4a4aa7ba5fe2fa60d1af

Clinical factors related to successful or unsuccessful cardioversion in the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE‐AF) randomized trial

Autor: Maciej Banach, Gregory Y.H. Lip, Michael Melino, Monika Kozieł, James Jin, Naab Al-Saady, Shannon M Winters, José L. Merino, Andreas Goette

Publikováno v: Journal of Arrhythmia
Journal of Arrhythmia, Vol 36, Iss 3, Pp 430-438 (2020)

Background EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation evaluated use of nonvitamin K antagonist oral anticoagulant edoxaban vs enoxaparin‐warfarin in patients with nonvalvular atrial fibrillation undergoing

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb5cc1dde1ddac0955b0454604894650
https://hdl.handle.net/11268/8920

P6369The relationship of renal function to outcome: a post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion Of Atrial Fibrillation (ENSURE-AF) study

Autor: Maciej Banach, Andreas Goette, Naab Al-Saady, Michael D. Ezekowitz, G Y H Lip

Publikováno v: European Heart Journal. 38

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d08a2163cb674628ee091366cc5fd31f
https://doi.org/10.1093/eurheartj/ehx493.p6369

Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial

Autor: Dmitry Zamoryakhin, Michael D. Ezekowitz, Jindřich Špinar, Béla Merkely, José L. Merino, James Jin, Victor Fernandez, Valeriy Batushkin, Mykola Kushnir, Natalya Pelekh, Joris R. de Groot, Sergey Zenin, Michael A. Grosso, Andreas Goette, Naab Al-Saady, Mlchele Mercuri, Gregory Y.H. Lip, Michael Melino

Publikováno v: Goette, A, Merino, J L, Ezekowitz, M D, Zamoryakhin, D, Melino, M, Jin, J, Mercuri, M F, Grosso, M A, Fernandez, V, Al-Saady, N, Pelekh, N, Merkely, B, Zenin, S, Kushnir, M, Spinar, J, Batushkin, V, de Groot, J R & Lip, G Y H 2016, ' Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF) : a randomised, open-label, phase 3b trial ', Lancet, vol. 388, no. 10055, pp. 1995-2003 . https://doi.org/10.1016/S0140-6736(16)31474-X
Lancet, 388(10055), 1995-2003. Elsevier Limited
ResearcherID

Background Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and systemic embolism in patients with atrial fibrillation and is associated with less bleeding than well controlled warfarin therapy. Few safety data about ed

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11562255235d068d1bf195c1d25509a6
https://pubmed.ncbi.nlm.nih.gov/27789020

ASSESSMENT OF STATISTICAL POWER IN FACTOR XA INHIBITOR NON-INFERIORITY TRIALS OF ELECTRICAL CARDIOVERSION IN ATRIAL FIBRILLATION

Autor: David McKenzie, Naab Al-Saady, A. John Camm, Jonathan F. Plehn

Publikováno v: Journal of the American College of Cardiology. 65(10)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a380c8a7469e7ee241614a9fc4d91f6e